Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gottfried Von Keudell, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer J. 2022 02 10; 12(2):29. PMID: 35145059; PMCID: PMC8831497.
    Citations:    Fields:    Translation:Humans
  2. Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Commun Biol. 2022 01 11; 5(1):39. PMID: 35017636; PMCID: PMC8752757.
    Citations: 2     Translation:HumansCells
  3. Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leuk Lymphoma. 2022 03; 63(3):751-754. PMID: 34949132.
    Citations: 2     Fields:    Translation:Humans
  4. Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma. 2022 04; 63(4):821-833. PMID: 34865586.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  5. Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, Matasar MJ, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Successful implementation of outpatient R?±?DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leuk Lymphoma. 2022 04; 63(4):876-884. PMID: 34784853.
    Citations:    Fields:    Translation:Humans
  6. Mortensen SJ, Smith RDJ, von Keudell GR, Smith MR, Weaver MJ, Nazarian A, von Keudell AG. Substance-Related Found-Down Compartment Syndrome: A Systematic Review. J Orthop Trauma. 2021 07 01; 35(7):e247-e253. PMID: 33177431.
    Citations: 1     Fields:    Translation:Humans
  7. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021 10 01; 39(28):3109-3117. PMID: 34170745; PMCID: PMC9851707.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  8. Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021 06 16; 11(6):113. PMID: 34135307; PMCID: PMC8209097.
    Citations: 10     Fields:    Translation:Humans
  9. von Keudell G, Salles G. The role of tazemetostat in relapsed/refractory follicular lymphoma. Ther Adv Hematol. 2021; 12:20406207211015882. PMID: 34104370; PMCID: PMC8165870.
    Citations: 5     
  10. Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021 01 07; 137(1):39-48. PMID: 32730585; PMCID: PMC8555387.
    Citations: 12     Fields:    Translation:Humans
  11. Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol. 2021 01 06; 14(1):5. PMID: 33407745; PMCID: PMC7789477.
    Citations: 7     Fields:    Translation:HumansAnimals
  12. Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020 10 13; 4(19):4669-4678. PMID: 33002134.
    Citations: 20     Fields:    Translation:HumansCells
  13. Sermer D, Bobillo S, Dogan A, Zhang Y, Seshan V, Lavery JA, Batlevi C, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Palomba ML, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Adv. 2020 07 28; 4(14):3382-3390. PMID: 32722781; PMCID: PMC7391142.
    Citations:    Fields:    Translation:Humans
  14. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020 07 17; 10(7):74. PMID: 32678074.
    Citations: 32     Fields:    Translation:HumansPHPublic Health
  15. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano JF, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Luminari S, Marcheselli L, Federico M, Younes A. Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020 02; 126:78-90. PMID: 31927165; PMCID: PMC7331469.
    Citations: 11     Fields:    Translation:Humans
  16. Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J. Follicular lymphoma. Nat Rev Dis Primers. 2019 12 12; 5(1):83. PMID: 31831752.
    Citations: 58     Fields:    Translation:Humans
  17. von Keudell G, Moskowitz AJ. The Role of PI3K Inhibition in Lymphoid Malignancies. Curr Hematol Malig Rep. 2019 10; 14(5):405-413. PMID: 31359259.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  18. von Keudell G, Younes A. Will GALEN become more RELEVANT? Lancet Haematol. 2019 08; 6(8):e391-e392. PMID: 31296424.
    Citations:    Fields:    Translation:Humans
  19. Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Reply to H.J.A. Adams et al. J Clin Oncol. 2019 04 01; 37(10):853-854. PMID: 30742563.
    Citations:    Fields:    Translation:Humans
  20. von Keudell G, Younes A. Novel therapeutic agents for relapsed classical Hodgkin lymphoma. Br J Haematol. 2019 01; 184(1):105-112. PMID: 30536386.
    Citations: 8     Fields:    Translation:Humans
  21. Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. J Clin Oncol. 2018 Oct 25; JCO1800359. PMID: 30359156.
    Citations: 8     Fields:    
  22. Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. J Clin Oncol. 2018 Oct 04; JCO1800122. PMID: 30285558; PMCID: PMC6241679.
    Citations: 11     Fields:    
  23. Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017 Oct 01; 123(19):3763-3771. PMID: 28640385; PMCID: PMC5610636.
    Citations: 11     Fields:    Translation:Humans
  24. Deng X, Von Keudell G, Suzuki T, Dohmae N, Nakakido M, Piao L, Yoshioka Y, Nakamura Y, Hamamoto R. PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget. 2015 Nov 03; 6(34):35173-82. PMID: 26460953; PMCID: PMC4742097.
    Citations: 20     Fields:    Translation:HumansCells
  25. von Keudell G, Larson RA. Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. J Clin Oncol. 2016 05 01; 34(13):e123-5. PMID: 24733791.
    Citations: 1     Fields:    Translation:HumansCells
  26. von Keudell G, Sanchorawala V, O'Hara C, C Seldin D, Sloan JM. Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. Amyloid. 2014 Jun; 21(2):124-7. PMID: 24471777.
    Citations: 1     Fields:    Translation:Humans
  27. Kustikova OS, Geiger H, Li Z, Brugman MH, Chambers SM, Shaw CA, Pike-Overzet K, de Ridder D, Staal FJ, von Keudell G, Cornils K, Nattamai KJ, Modlich U, Wagemaker G, Goodell MA, Fehse B, Baum C. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood. 2007 Mar 01; 109(5):1897-907. PMID: 17119121; PMCID: PMC1801061.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Von Keudell's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (119)
Explore
_
Co-Authors (6)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.